PF-06730512: Clinical Trials

1 trial of PF-06730512, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Terminated 1

Follow PF-06730512: new trials by email Literature Review of PF-06730512 trials Research Report on PF-06730512

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
PF-06730512 - Focal Segmental Glomerulosclerosis (FSGS)
Phase 2TerminatedPfizer472018-10-152024-04-18

Conditions studied

Glomerulosclerosis, Focal Segmental (1)  ·  Proteinuria (1)

Sponsors

Pfizer (1)

Countries

Canada (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Japan (1)  ·  Mexico (1)  ·  Poland (1)  ·  Slovakia (1)  ·  Spain (1)  ·  United Kingdom (1)  ·  United States (1)

Results publications

PMID 34169203

NIH funding

2019 (1)